All for Statins and Statins for All; An Update

被引：21

作者：

Agouridis, Aris P. ^{[1
,2
]}

Elisaf, Moses S.

Nair, Devaki R. ^{[2
]}

Mikhailidis, Dimitri P. ^{[3
]}

机构：

[1] Univ Ioannina, Sch Med, Dept Internal Med, GR-45110 Ioannina, Greece

[2] Royal Free London Fdn Trust, Dept Clin Biochem, Vasc Dis Prevent Clin, London, England

[3] UCL, Dept Clin Biochem, Vasc Dis Prevent Clin, Sch Med, London NW3 2QG, England

来源：

CURRENT PHARMACEUTICAL DESIGN | 2016年 / 22卷 / 01期

关键词：

Statin; cardiovascular disease; cardiovascular risk factors; prevention; C-REACTIVE PROTEIN; INTIMA-MEDIA THICKNESS; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-ARTERY-DISEASE; HIGH-DOSE ATORVASTATIN; RANDOMIZED CONTROLLED-TRIALS; LIPID-LOWERING THERAPY; CHRONIC KIDNEY-DISEASE; FIBRATE COMBINATION THERAPY; TRANSIENT ISCHEMIC ATTACK;

D O I：

10.2174/1381612822666151109111511

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Statins exert beneficial effects on cardiovascular [CV] outcomes as well as on inflammation and oxidative stress. The widespread use of statins for both primary and secondary CV disease prevention is based on the evidence from large randomized controlled trials. The benefits of statin treatment outweigh any harm in high risk patients. In this narrative review, we provide an update on several aspects of statin treatment based on the most recent evidence in this field.

引用

页码：18 / 27

页数：10

共 184 条

[1]

Agouridis AP, 2010, CURR PHARM DESIGN, V16, P3401, DOI 10.2174/138161210793563464

[2]

Agouridis AP, 2015, CURR MED RES OPIN, P1

[3]

Agouridis AP, 2015, EXPERT OPIN IN PRESS

[4]

Agouridis AP, 2011, EXPERT REV CARDIOVAS, V9, P355, DOI [10.1586/ERC.11.4, 10.1586/erc.11.4]

[5] Statins and breast cancer prognosis: evidence and opportunities [J].

Ahern, Thomas P. ;

Lash, Timothy L. ;

Damkier, Per ;

Christiansen, Peer M. ;

Cronin-Fenton, Deirdre P. .

LANCET ONCOLOGY, 2014, 15 (10) :E461-E468

[6] Phenotype Standardization for Statin-Induced Myotoxicity [J].

Alfirevic, A. ;

Neely, D. ;

Armitage, J. ;

Chinoy, H. ;

Cooper, R. G. ;

Laaksonen, R. ;

Carr, D. F. ;

Bloch, K. M. ;

Fahy, J. ;

Hanson, A. ;

Yue, Q-Y ;

Wadelius, M. ;

Maitland-van der Zee, A. H. ;

Voora, D. ;

Psaty, B. M. ;

Palmer, C. N. A. ;

Pirmohamed, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (04) :470-476

[7] Coronary Heart Disease Risk in Patients With Stroke or Transient Ischemic Attack and No Known Coronary Heart Disease Findings From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial [J].

Amarenco, Pierre ;

Goldstein, Larry B. ;

Sillesen, Henrik ;

Benavente, Oscar ;

Zweifler, Richard M. ;

Callahan, Alfred, III ;

Hennerici, Michael G. ;

Zivin, Justin A. ;

Welch, K. Michael A. .

STROKE, 2010, 41 (03) :426-430

[8] Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial [J].

Amarenco, Pierre ;

Goldstein, Larry B. ;

Messig, Michael ;

O'Neill, Blair J. ;

Callahan, Alfred, III ;

Sillesen, Henrik ;

Hennerici, Michael G. ;

Zivin, Justin A. ;

Welch, K. M. A. .

STROKE, 2009, 40 (07) :2486-2492

[9]

Amarenco P, 2006, NEW ENGL J MED, V355, P549

[10]

[Anonymous], 2007, J VASC SURG

← 1 2 3 4 5 6 7 8 9 10 →